Thrombotic risk in antiphospholipidic syndrome: From hypothesis to current evidence (Review)

Gavriș,Claudia Mihaela; Nedelcu,Laurențiu Dănuț; Pascu,Alina Mihaela

doi:10.3892/etm.2021.9718

Thrombotic risk in antiphospholipidic syndrome: From hypothesis to current evidence (Review)

Authors:
- Claudia Mihaela Gavriș
- Laurențiu Dănuț Nedelcu
- Alina Mihaela Pascu
View Affiliations

Affiliations: Faculty of Medicine, ‘Transilvania University’ of Brașov, 500036 Brasov, Romania
Published online on: January 26, 2021 https://doi.org/10.3892/etm.2021.9718
Article Number: 287

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thirty‑five years after it was first described, antiphospholipid syndrome (APS) is unanimously recognized as a systemic autoimmune disease, a major acquired thrombophilia, which can affect any arterial or venous vascular territory, explaining the great diversity of clinical manifestations. The current classification criteria updated in the International Consensus Statement for Definite Antiphospholipid Syndrome from Sydney cannot explain alone the unpredictable evolution with thrombotic events of the patients diagnosed with APS. Although the link to genetics and epigenetics has not been clearly defined as in other autoimmune diseases, it is clear that a proper stratification of thrombotic risk in the era of personalized medicine must include classic biological markers (antiphospholipid antibodies, aPL), along with the already recognized phenotypes, non‑conventional serological markers, and additional genetic risk factors for thrombosis. Moreover, with advancing age, a patient with APS develops other thrombotic risk factors which include: hypertension and dyslipidemia among others. According to the classification criteria, a patient is considered to have a low, moderate or high thrombotic risk. In clinical practice, patients with the same risk score may have completely different evolutions in terms of the recurrence of thrombosis. Concerning this approach, it appears that new non‑conventional serological markers, phenotype‑assessment and genetic determinants have an increasing importance and should be reconsidered in a proper thrombotic risk evaluation in patients with APS, compared to the initial concept of APS as first defined.

View Figures

View References

1	Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, et al: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 4:295–306. 2006.PubMed/NCBI View Article : Google Scholar
2	Gardiner C, Hills J, Machin SJ and Cohen H: Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus. 22:18–25. 2013.PubMed/NCBI View Article : Google Scholar
3	Galli M, Reber G, de Moerloose P and de Groot PG: Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost. 6:399–401. 2008.PubMed/NCBI View Article : Google Scholar
4	Tincani A, Andreoli L, Casu C, Cattaneo R and Meroni P: Antiphospholipid antibody profile: Implications for the evaluation and management of patients. Lupus. 19:432–435. 2010.PubMed/NCBI View Article : Google Scholar
5	Kelchtermans H, Pelkmans L, de Laat B and Devreese KM: IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: A critical review of their association with thrombosis. J Thromb Haemost. 14:1530–1548. 2016.PubMed/NCBI View Article : Google Scholar
6	Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, et al: EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 78:1296–1304. 2019.PubMed/NCBI View Article : Google Scholar
7	Garcia D and Erkan D: Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 378:2010–2021. 2018.PubMed/NCBI View Article : Google Scholar
8	Montagnana M, Lippi G and Danese E: An overview of thrombophilia and associated laboratory testing. Methods Mol Biol. 1646:113–135. 2017.PubMed/NCBI View Article : Google Scholar
9	Galli M, Luciani D, Bertolini G and Barbui T: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood. 101:1827–1832. 2003.PubMed/NCBI View Article : Google Scholar
10	Chayoua W, Kelchtermans H, Moore GW, Musiał J, Wahl D, de Laat B and Devreese KM: Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays. J Thromb Haemost. 16:2016–2023. 2018.PubMed/NCBI View Article : Google Scholar
11	Hughes GR and Khamashta MA: ‘Seronegative antiphospholipid syndrome’: An update. Lupus. 28:273–274. 2019.PubMed/NCBI View Article : Google Scholar
12	Chayoua W, Kelchtermans H, Gris JC, Moore GW, Musiał J, Wahl D, de Groot PG, de Laat B and Devreese KM: The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost. 18:169–179. 2020.PubMed/NCBI View Article : Google Scholar
13	Campello E, Spiezia L, Adamo A and Simioni P: Thrombophilia, risk factors and prevention. Expert Rev Hematol. 12:147–158. 2019.PubMed/NCBI View Article : Google Scholar
14	Gavris C, Poroch V, Simion L, Baracan A, Toader E and Pascu AM: Biochemical markers with low-grade inflammation as predictors of thrombotic events in antiphospholipid syndrome. Rev Chim. 68:1586–1590. 2017.
15	Devreese KM, Ortel TL, Pengo V and de Laat B: Laboratory criteria for antiphospholipid syndrome: Reply. J Thromb Haemost. 16:2117–2119. 2018.PubMed/NCBI View Article : Google Scholar
16	De Craemer AS, Musial J and Devreese KM: Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost. 14:1779–1787. 2016.PubMed/NCBI View Article : Google Scholar
17	Iwaniec T, Kaczor MP, Celińska-Löwenhoff M, Polański S and Musiał J: Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome. Thromb Res. 153:90–94. 2017.PubMed/NCBI View Article : Google Scholar
18	Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F and Pastori D: Seronegative antiphospholipid syndrome: Refining the value of ‘non-criteria’ antibodies for diagnosis and clinical management. Haematologica. 105:562–572. 2020.PubMed/NCBI View Article : Google Scholar
19	Sciascia S, Baldovino S, Schreiber K, Solfietti L, Radin M, Cuadrado MJ, Menegatti E, Erkan D and Roccatello D: Thrombotic risk assessment in antiphospholipid syndrome: The role of new antibody specificities and thrombin generation assay. Clin Mol Allergy. 14(6)2016.PubMed/NCBI View Article : Google Scholar
20	Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G and Dragon-Durey MA: Prevalence and Significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol. 9(2971)2018.PubMed/NCBI View Article : Google Scholar
21	Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, Horita T, Yasuda S and Koike T: Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 64:504–512. 2012.PubMed/NCBI View Article : Google Scholar
22	Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA and Bertolaccini ML: GAPSS: The Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 52:1397–1403. 2013.PubMed/NCBI View Article : Google Scholar
23	Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA and Bertolaccini ML: Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 111:354–364. 2014.PubMed/NCBI View Article : Google Scholar
24	Sciascia S, Radin M, Cecchi I, Bertolaccini ML, Bertero MT, Rubini E, Vaccarino A, Bazzan M, Giachino O, Baldovino S, et al: Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. Rheumatology (Oxford), 2019 (Ahead of print).
25	Forastiero R, Martinuzzo M, Adamczuk Y, Varela ML, Pombo G and Carreras LO: The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Haematologica. 86:735–741. 2001.PubMed/NCBI
26	Pengo V: A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost. 6:1048–1049. 2008.PubMed/NCBI View Article : Google Scholar
27	Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, et al: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 8:237–242. 2010.PubMed/NCBI View Article : Google Scholar
28	Wahl D: ‘Antiphospholipids’: The more, the worse? Blood. 131:2092–2094. 2018.PubMed/NCBI View Article : Google Scholar
29	Atsumi T, Bertolaccini ML and Koike T: Genetics of antiphospholipid syndrome. Rheum Dis Clin North Am. 27:565–572. 2001.PubMed/NCBI View Article : Google Scholar
30	Castro-Marrero J, Balada E, Vilardell-Tarrés M and Ordi-Ros J: Genetic risk factors of thrombosis in the antiphospholipid syndrome. Br J Haematol. 147:289–296. 2009.PubMed/NCBI View Article : Google Scholar
31	Yonal I, Hindilerden F, Hancer VS, Artim-Esen B, Daglar A, Akadam B, Nalcaci M and Diz-Kucukkaya R: The impact of platelet membrane glycoprotein Ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome. Thromb Res. 129:486–491. 2012.PubMed/NCBI View Article : Google Scholar
32	Iuliano A, Galeazzi M and Sebastiani GD: Antiphospholipid syndrome's genetic and epigenetic aspects. Autoimmun Rev. 18(102352)2019.PubMed/NCBI View Article : Google Scholar
33	Diz-Kucukkaya R, Hancer VS, Artim-Esen B, Pekcelen Y and Inanc M: The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis. 29:303–309. 2010.PubMed/NCBI View Article : Google Scholar
34	Berman H, Ugarte-Gil MF, Espinosa G, Tàssies D, Monteagudo J, Reverter JC and Cervera R: Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome? Clin Exp Rheumatol. 31:926–932. 2013.PubMed/NCBI
35	Hotoleanu C: Genetic risk factors in venous thromboembolism. Adv Exp Med Biol. 906:253–272. 2017.PubMed/NCBI View Article : Google Scholar
36	Negrini S, Pappalardo F, Murdaca G, Indiveri F and Puppo F: The antiphospholipid syndrome: From pathophysiology to treatment. Clin Exp Med. 17:257–267. 2017.PubMed/NCBI View Article : Google Scholar
37	Islam MA, Khandker SS, Alam F, Kamal MA and Gan SH: Genetic risk factors in thrombotic primary antiphospholipid syndrome: A systematic review with bioinformatic analyses. Autoimmun Rev. 17:226–243. 2018.PubMed/NCBI View Article : Google Scholar